In particular, a recent study showed that, among DLBCL patients treated with R-CHOP chemotherapy, those having c-myc gene rearrangements had an inferior prognosis compared to those without c-myc translocations, and it was suggested that treatment regimens similar to those used in BL would be more appropriate for these cases [11]. This evidence concerns the gene MYC and Burkitt lymphoma.